The unstimulated platelet surface contains a specific and saturable binding site for high molecular weight kininogen (HK) and low molecular weight kininogen (LK). Investigations were performed with purified heavy and light chains of HK t o determine which portion(s) of the HK molecule binds t o the platelet surface. Purified 64-Kd heavy chain of HK and 56-Kd light chain of HK, independently, inhibited '%HK binding t o unstimulated platelets with a 50% inhibitory concentration ( I C, ) of 84 nmol/L (apparent Ki, 30 nmol/L) and 30 nmol/L (apparent Ki, 11 nM), respectively. The ability of each of the purified chains of HK t o independently inhibit '%HK binding was not due t o cleavage, reduction, and alkylation of the protein, because two-chain HK, produced by treating HK the same way as purifying the separate chains, inhibited binding similarly t o intact HK. Further, purified LK alone inhibited '%HK binding t o platelets (Ki, 17 f 1 nmol/L, n = 7). The 64-Kd heavy chain of HK was a competitive inhibitor on a reciprocal plot of '%HK-platelet binding with an apparent Ki of 28 f 6 nmol/L (n = 4). Independently, purified 56-Kd light chain of HK was also found t o be a competitive inhibitor of HE MEMBRANE EXPRESSION of the plasma kini-T nogens on platelets, granulocytes, and endothelial cells has a number of functions.' Since the plasma kininogens are parent molecules for bradykinin, a potent vasoactive peptide, their cell membrane expression may serve to modulate the 'delivery of this peptide to its receptor(s). The, membrane expression of the kininogens is also known to modulate thrombin qptivation of platelets, primarily by noncompetitively blocking proteolytically active thrombin from binding* and also by inhibiting the proteolytic activity of externalized platelet calpain after On granulocytes and activated platelets, high molecular weight kininogen (HK) has been characterized to be a noncompetitive inhibitor of fibrinogen binding." The platelet membrane expressiqp of HK is also essential for factor XI/XIa platelet binding."
T nogens on platelets, granulocytes, and endothelial cells has a number of functions.' Since the plasma kininogens are parent molecules for bradykinin, a potent vasoactive peptide, their cell membrane expression may serve to modulate the 'delivery of this peptide to its receptor(s). The, membrane expression of the kininogens is also known to modulate thrombin qptivation of platelets, primarily by noncompetitively blocking proteolytically active thrombin from binding* and also by inhibiting the proteolytic activity of externalized platelet calpain after On granulocytes and activated platelets, high molecular weight kininogen (HK) has been characterized to be a noncompetitive inhibitor of fibrinogen binding." The platelet membrane expressiqp of HK is also essential for factor XI/XIa platelet binding."
In plasma, HK cqn bind prekallikrein and factor XI, '3-'5 presumably to bring these zymogens to negatively charged surfaces for activation. When cells are disrupted, physiologic negatively charged surfaces such as sulfatides and glycosamin~giycans'~~'~ could be exposed for activation of factor XI1 and, subsequently, prekallikrein and factor XI associated with these surfaces by being in-complex with HK. Since HK binds to artificial or biologic negatively charged surfaces by a histidine-rich region on its light hai in,''.'^ it has been presumed that the cell binding region on HK would also be located on its 56-Kd light chain. However, recent evidence from our laboratory shows that low molecular weight kininogen (LK) directly binds to platelets: and other preliminary evidence suggests that the cell binding region on kininogens may be exclusively on their heavy chains.w22' The following studies were undertaken to determine if only the heavy chain of HK participates in binding to the membrane of unstimulated platelets. bound to platelets is cleaved by plasma and tissue kallikeins at a slower rate than unbound HK. This latter fact suggests that the rate at which bradykinin is liberated from HK is influenced by its being cell-bound.
were purchased from BioRad, Richmond, CA. All other materials were obtained from Sigma Chemical, St Louis, MO, and were the best grade commercially available. Pooled normal plasmas (lots N10 and 313D) were purchased from George King Biomedical, Overland Park, KS. Normal donors were young women and men (age, 21 to 45 years) who were receiving no medication and who gave written informed consent. Fresh blood was collected and platelet-rich plasma and platelet-poor plasma were prepared as previously described.' Total kininogen-deficient plasma (plasma deficient in both HK and LK) was donated by M. Williams, Philadelphia, PA. HK-deficient plasma, Fitzgerald trait, was a generous gift of Dr A.G. Scicli, Henry Ford Hospital, Detroit, MI.
HK was purified using a modified method of Kerbiriou and Griffin" as previously reported.' These preparations of HK, when reduced with 2% P-mercaptoethanol and applied to a 71/2% SDS-PAGE," migrated mostly as a single band at 120 Kd with greater than 98% purity and with a specific activity of 12 to 20 Ulmg.' Purified HK was radiolabeled with Na "' I using lodogen by the method of Fraker and Speck" under conditions previously described.' The specific radioactivity of the protein varied from 3 to 16 pCi/pg, with a mean value of 10 pCi/pg and 60% of the molecules were iodinated (range, 14% to 85%). Radioiodine incorporation into protein was determined by the ratio of atoms of '"I incorporated into the protein as determined by assaying radioactivity in a gamma counter to the molecules of recovered "'I-HK as determined by antigen concentration performed by radial immunodiffusion. The radiolabeled protein was greater than 95% trichloroacetic acid-precipitable and retained greater than 95% of its procoagulant activity, as well as its antigenic properties. ' The 64-Kd heavy and 56-Kd light chains of HK were prepared by the procedure of Kerbiriou and Griffin from a partially cleaved preparation of purified HK (see "HK," Fig I) ." The HK preparation used for the purification of these chains was partially cleaved during its purification from plasma, resulting in a preparation of HK that was partially kinin-free. Since this preparation of HK was not good enough for radiolabeling for binding studies, it was used to purify the kinin-free chains of HK. Human urinary kallikrein Plusmu and p/ute/ets.
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(generously provided by Dr Harry Margolius, Medical University of South Carolina, Charleston) was incubated with HK at approximately a 1/100 molar ratio (33 pg HUK in 33 pLwas added into 10 mgHKin2mLof 10mmol/LTris,0.15mol/LNaCI,pH7.8)for 16 hours at 37°C to completely cleave the HK for the separation of its heavy and light chains. The fully cleaved HKwas then reduced with 50 mmol/L D I T for 1 hour, followed by alkylation in the dark with 120 mmol/L iodoacetamide for 30 minutes, followed by dialysis against 0.01 mol/L sodium acetate, 0.04 mol/L NaCI, pH 5.4. This material was applied to an SP Sephadex column in 0.01 mol/L sodium acetate, 0.08 mol/L NaCI, pH 5.4. The heavy chain of HK was not adsorbed to the cation exchanger, while the light chain was eluted with a linear NaCl gradient from 0.08 mol/L to 0.5 mol/L.
On an 8% SDS-PAGE," the heavy chain of HK was a single band at h4 Kd, and the light chain of HK was a single band at 56 Kd (Fig  I) . The purified 64-Kd heavy chain had no procoagulant activity; the purified 56-Kd light chain had a specific activity of 8 U/mg. On immunoblot using monoclonal antibodies directed to the heavy and light chains of kininogen,?' the purified light chain of HK was only detected by the light-chain antibody. Purified light chain of HKwas radiolabeled with Na "'I using lodogen as previously reported for HK. The specific radioactivity of the protein was 5.8 pCi/pg and 15% of the molecules were iodinated. Radiolabeled light chain of HK was greater than 95% trichloroacetic acid-precipitable and retained greater than 90% of its procoagulant activity.
LK was purified as previously described." LK was characterized as having a single immunoprecipitin arc to antisera directed toward total human plasma kininogen antigen,'" but no procoagulant ability to correct the clotting defect of total kininogen-deficient plasma." Further, on immunoblot, it was only detected by monoclonal antibodies directed against the heavy chain of the kininogens." On reduced SDS-PAGE, purified LK migrated as a single band at 66 Kd (Fig 1) . LK was also radiolabeled with Na "' 1 using lodogen by the method of Fraker and Speck'' as previously reported." The specific radioactivity of the "'I-LK was 7 pCi/pg and greater than 21% of the molecules were iodinated. The radiolabeled LK was greater than 95% trichloroacetic acidprecipitable and retained its antigenic properties." HK procoagulant activity was measured by a one-stage, kaolin-activated coagulant a s s a p using total kininogen-deficient plasma as substrate. Samples were compared with a daily standard curve of pooled normal human plasma diluted 1/10 to 1/1,OOO with 0.01 mol/L Tris and 0.15 mol/L NaCl at pH 7.4. One unit was defined as that amount of HK procoagulant activity in 1 mL of pooled normal plasma. HK antigen was also assayed by electroimmunodiffusion using monospecific antisera to the light chain of HK as described previously.' LK antigen was measured by radial immunodiffusion using antisera directed toward total human kininogen antigen.% The amount of LK was determined by comparison with Fitzgerald plasma, which has been previously characterized for its concentration of LK?' The concentration of the purified light and heavy chains of HK were also determined by the protein assay of Bradford" using bovine serum albumin (BSA) as a standard, as well as radial immunodiffusion using antisera that detects total kininogen?6 Immunoblotting was performed by a modified procedure of Towbin et with monoclonal antibodies to kininogen as previously reported.25
Platelet-rich plasma34 was obtained from citrated human blood collected into polypropylene tubes and gel filtered on a Sepharose 2B c01umn~~ equilibrated in calcium-free Tyrode's buffer (0.135 mol/L NaC1,2.7 mmol/L KCI, 11.9 mmol/L NaHCO,, 0.36 mmol/L NaHzP04, pH 7.35) with Hepes (14.7 mmol/L), BSA (1 mg/mL), and dextrose (3.5 mg/ mL).36 This buffer contained 1 mmol/L M e and is called Hepes buffer throughout the text. Platelets prepared by this technique had less than 0.8 ng HK antigen per 10' platelets on their membrane: a value which is less than 2% of the total platelet HK as determined by a competitive enzyme-linked immunosorbent assay (ELISA)' and less than 10% of the total amount of exogenous '"I-HK that can bind to unstimulated platelets: Washed platelets were counted electronically (Coulter Electronics, Hialeah, EL).
In all binding experiments, platelets were at a final concentration of 2 x 108/mL. In a typical binding experiment, 300 pL of gel-filtered platelets in Hepes buffer, pH 7.35, were incubated at 37°C without stirring in a polypropylene tube (Sarstedt, Princeton, NJ) with radiolabeled HK, light chain of HK or LK, and additions (ZnZ+, unlabeled competitors, or buffer) to a total volume of 350 pL. After incubation, 50-pL aliquots were removed (in triplicate) for each experimental point for determination of total counts or for centrifugation at 9,600 X g at 23°C for 2 minutes in a microfuge (Model B, Beckman Instruments, Cedar Grove, NJ) through a 200-pL oil gradient (1 part Apiezon A/9 parts N-butylphthalate) in polypropylene microsediment tubes with narrow bore extended tips (Sarstedt) to separate bound from free counts. After the supernatant was carefully removed, the tips 
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containing the pellet were amputated and counted in a rack gamma counter (LKB Instruments, Rockville, MD) to determine bound counts. Unbound or free counts were determined by substracting bound counts from total counts.
To study the influence of the purified heavy and light chains of HK on lZ5I-HK binding to platelets, competitive inhibition of binding experiments were performed. In these studies '%HK (4.16 nmol/L) was added to platelets in Hepes buffer containing Znz+ (50 pmol/L), Ca2' (2 mmol/L), and either purified heavy or light chain of HK in a 0 to 80-fold molar excess for 15 minutes, prior to centrifugation through oil. A 15-minute incubation of the radioligand with platelets with or without competitors was performed, because in previous studies it was learned that the '"I-HK-and '"I-LK-platelet binding interaction was fully reversible at this time!, ' Competitive inhibition of binding studies by HK, cleaved, reduced, and alkylated HK, and LK on '=I-HK binding to platelets were also performed. In these investigations, lZ5I-HK (8.3 nmol/L) was incubated with platelets in Hepes buffer containing 50 pmol/L Zn2+ and increasing concentrations of the competitor in 0 to 100-fold molar excess.
A second approach was used to confirm the results of the experiments of competitive inhibition of binding. Concentrationdependent binding experiments were performed with '%HK in the absence or presence of unlabeled HK, the 64-Kd heavy chain of HK, or the 56-Kd light chain of HK. In these experiments, increasing concentrations of '"I-HK (0.83 to 7.5 nmol/L) were added to an incubation mixture with platelets in Hepes buffer containing Zn2+ (50 pmol/L) and Ca2+ (2 mmol/L) in the absence or presence of 10 to 37.5 nmol/L competitor. Incubations were performed for 15 minutes before centrifugation through oil. Nonspecific binding, which was usually less than 35% of total binding: was determined by binding identical concentrations of '"I-HK and additions in the presence of a 50-fold molar excess of the unlabeled competitor. In all instances, specific binding of the radioligand to platelets was determined by subtracting nonspecific binding (binding in the presence of a 50-fold molar excess unlabeled ligand) from total binding according to the procedure of Schreiber et al?' .' ' Direct binding of '"I-LK to platelets was measured using '"I-LK (10 nmol/L) added to cell suspensions in Hepes buffer containing 50 pmol/L Zn2+ as previously reported! Direct '"I-HK concentration-dependent binding experiments were performed as previously reported: The direct binding of '"I-light chain of HK to platelets was determined using 5 nmol/L radiolabeled light chain added to platelets in Hepes buffer containing 50 pmol/L Zn2+. In all instances of direct binding experiments, nonspecific binding was determined by the addition of a 50-fold molar excess of the unlabeled ligand. For personal use only. on October 3, 2017. by guest www.bloodjournal.org From reversible, and saturable binding. Inhibition of concentrationdependent binding experiments was analyzed by double reciprocal plots of l/specifically bound versus l/free. The lines for the reciprocal plot were graphed after being analyzed by a weighted linear regression analysis," which was determined by using the formula of n -2/(SEM)2,42 where n is the number of determinations of added radioligand at one concentration and the SEM is determined from all the experiments of the specifically bound radioligand at that concentration. The apparent Ki of unlabeled HK or its purified chains to inhibit ''%HK-platelet binding was determined by a secondary plot of the slope of the double reciprocal plot versus inhibitor concentration." The apparent Ki was also independently calculated by a computer program for competitive inhibition kinetics" using a Model 4P Computer, Tandy Corporation, Fort Worth, TX. Calculation of the Kd of direct '%HK binding to platelets was performed by the method of Scatchard!' Briefly, a linear regression was determined from the ratio of the bound radioligand/free radioligand versus bound, after nonspecific binding was subtracted from both.
The electrophoretic mobility of platelet-bound '"I-HK was determined by SDS-PAGEu followed by autoradiography. In these experiments, the platelet pellets were pretreated with 1 mmol/L leupeptin to prevent cleavage by calpain when solubilized with SDS2 These solubilized platelets were then reduced with p-mercaptoethanol (5% vol/vol), followed by boiling for 5 minutes before application to the gel. Additionally, the ability of purified plasma kallikrein (4 nmol/L) or recombinant human urinary kallikrein (15 nmol/L) to cleave platelet-bound "'I-HK was assessed. In these experiments, 2 mL of platelets (2.5 x lo8 platelets/mL) in Hepes buffer containing Zn2+ (50 pmol/L) were made 8.3 nmol/L with lZI-HK after incubation for 15 minutes, platelets were separated from their suspension media by centrifugation through an oil gradient and the platelet pellet was washed once by centrifugation and then resuspended in one fifth of the volume with Hepes buffer (1.25 x lo9 platelets/mL, final concentration). Since approximately 3.5% of the added radioligand was bound to the platelet pellet, the final concentration of platelet-bound '%HK in the resuspended platelets was 1.5 nmol/L. Purified kallikreins were then added at the concentrations given above to the resuspended platelet pellets and at various times from the addition of the kallikrein (0 to 120 minutes), 5O-kL aliquots were removed. Preliminary experiments showed that the initial exposure of '=I-HK to the oil gradient did not alter the kininogen's susceptibility to cleavage by the kallikreins (data not shown). The platelet aliquots were then recentrifuged through another oil gradient, and the platelet pellets, after washing once by resuspension and centrifugation, were solubilized in SDS-PAGE sample buffer. Aliquots of the supernatant after the second centrifugation were also saved at each time point to represent platelet-bound '%HK that eluted from the platelet surface during the incubation period. Last, a concentration of '%HK identical to that found in the platelet suspension was incubated in buffer with the same concentration of the kallikreins, simultaneously with the cleavage experiments for platelet-bound radioligand. The autoradiograms of the dried SDS-PAGE from these experiments were scanned with a Hoefer Model GS 300 scanner (San Francisco, CA). The scans were then analyzed with Hoefer's GS 360, Version 2.2 software.
Characterization of bradykinin liberation f.om kallikrein-cleaved HK. Purified HK (9 pmol/L) in 0.01 mol/L Tris, 0.15 mol/L NaCI, pH 7.8, was incubated with purified plasma kallikrein (45 nmol/L) or purified recombinant human urinary kallikrein (170 nmol/L) for 16 hours at 37°C. At the end of the incubation, the reaction was stopped by the addition of SDS-PAGE sample buffer. Aliquots of the intact and cleaved HKs were electrophoresed on SDS-PAGE and stained with Coomassie blue. Other aliquots of Characterization ofplatelet-bound HK.
the intact and cleaved HKs were electroblotted onto nitrocellulose (0.1 pm pore size) by the procedure of Towbin et ai." After blocking the nitrocellulose with Blotto,& one immunoblot was performed using a primary goat antibody directed to human heavy and light chains of kininogen,% followed by a radiolabeled rabbit anti-goat antibody (Pel Freez, Rogers, AR). A second immunoblot on the intact and cleaved kininogens was performed using a murine monoclonal antibody to bradykinin" as the primary antibody followed by a radiolabeled sheep anti-mouse antibody (Pel Freez). The monoclonal antibody to bradykinin was generously provided by Dr Julie Chao, Medical University of South Carolina, Charleston. This antibody has the property to recognize the bradykinin sequence in intact kininogens on Western blots!'
RESULTS
Determination of the chain of HK that binds to platelets.
Initial experiments determined which of the purified chains of HK inhibited '"I-HK binding to platelets. When purified 56-Kd light chain of HK or 64-Kd heavy chain of HK were added in 25-fold or greater molar excess to '"I-HK, each chain independently inhibited the binding of '"I-HK to unstimulated platelets by 87% or greater and 74%, respectively. The ability of each of the purified chains of HK to inhibit lZI-HK binding to platelets were further evaluated in competitive inhibition of binding experiments (Fig 2A) . Increasing concentrations of the 64-Kd heavy chain of HK and purified 56-Kd light chain of HK, independently, were able to inhibit the binding of '"1-HK to unstimulated platelets. The IC,, of the purified heavy chain was 85 nmol/L (apparent Ki, 30 nmol/L), while the IC,, of purified light chain on '"I-HK binding to platelets was 30 nmol/L (apparent Ki, 11 nmol/L). The ability of the purified heavy or light chains of HK to inhibit lZI-HK-platelet binding did not result from the reduction and alkylation of the cleaved protein used to prepare the purified subunits. An equal molar mixture of two-chain HK produced by human urinary kallikrein cleavage, reduction, and alkylation inhibited '"I-HK binding to platelets with an apparent Ki of 16 2 4 nmol/L (n = 6), avalue similar to the apparent Ki of 14 & 2 nmol/L (n = 6) produced by unmodified HK (Fig 2B) . Furthermore, since LK and HK are identical in structure from the N-terminal portion of the molecule through the first 12 amino acid residues on the N-terminal portion of the light chain? we wanted to confirm that the heavy chain of LK contained a domain that bound to the platelet surface.' Increasing concentrations of LK inhibited '"I-HK binding to platelets with an apparent Ki of 17 2 1 nmol/L, n = 7 (mean k SEM) (Fig 2B) .
To confirm by an independent method that each chain of HK inhibited HK binding to unstimulated platelets, we performed concentration-dependent binding studies in the absence or presence of various competitors (intact HK, purified heavy chain of HK, and purified light chain of HK) (Fig 3) . To validate the use of this approach, initial binding experiments of '"I-HK were performed with HK as the competitor and the data were analyzed by reciprocal plots (Fig 3A) . Increasing concentrations of purified HK (10 to 25 nmol/L) competitively inhibited, as indicated by the common intercept on the ordinate, the ability of '"I-HK to bind to unstimulated platelets. On a secondary plot of the slope of the reciprocal plot versus the inhibitor concentra- tion" (data not shown), the apparent Ki of HK on lzI-HK binding was 7 nmol/L. When these data were independently analyzed by a computer program for competitive inhibition," the apparent Ki of HK on lSI-HK binding was found to be similar at 19 f 5 nmol/L, n = 3 (mean f SEM). These values were similar to the Kd (15 k 4 nmol/L, n = 6) determined by recent direct 'zI-HK-platelet binding experiments and analyzed by a Scatchard plot (data not shown), as well as to the Ki obtained with HK in the experiments of competitive inhibition of binding (14 f 2 nmol/L, n = 6) (Fig 2B) .
Concentration-dependent binding experiments were performed next, with the purified chains of HK as competitors.
Purified 64-Kd heavy chain of HK was found to be a competitive inhibitor by reciprocal plot of lz1-HK-platelet binding (Fig 3B) . Increasing concentrations of purified 64-Kd heavy chain of HK (10 to 37.5 nmol/L) inhibited For personal use only. on October 3, 2017. by guest www.bloodjournal.org From 'Z51-HK-platelet binding. On a secondary plot (data not shown), the apparent Ki of purified 64-Kd heavy chain of HK to inhibit '"I-HK-platelet binding was 17 nmol/L. Independent computer analysis of these data showed that the apparent Ki of the heavy chain of HK was 28 nmol/L +. 6 nmol/L, n=4 (mean f SEM). In Fig 3C, increasing concentrations of purified 56-Kd light chain of HK (10 to 25 nmol/L) was also found to produce competitive inhibition of '"I-HK binding to platelets. The apparent Ki of purified 56-Kd light chain of HK to inhibit '251-HK-platelet binding was 12 nmol/L when analyzed on a secondary plot of the slope of the double reciprocal plot versus inhibitor concentration (data not shown). When these data were independently analyzed by a computer program,44 an apparent Ki of 11 2 3 nmol/L, n=3 (mean 2 SEM), was found.
These indirect binding studies indicated that HK bound to platelets by two portions on the protein, one on the heavy chain and another on the light chain. The heavy chain binding region on the kininogens has been independently confirmed by the knowledge that LK directly binds to platelets.' To confirm that there is another region on the light chain of HK that binds to platelets, direct '"I-light chain of HK binding studies to unstimulated platelets were performed (Fig 4) . 'Z51-light chain binding to platelets was found to increase rapidly in the first 10 minutes and then slowly increase further to a maximum level at 80 minutes (Fig 4) . Nonspecific binding in the presence of a 50-fold molar excess unlabeled ligand was found to be less than 30% of the binding observed in the absence of competitor. The binding of '"I-light chain of HK to platelets was found to be specific, because only unlabeled light chain and intact HK were able to inhibit '"I-light chain binding (Table 1) . LK, Cls, C1 inhibitor, plasmin, factor XIII, and fibrinogen were not able to influence light chain binding to unstimu- lated platelets (Table 1) . Further, there was an absolute zinc requirement for 'zI-light chain of HK binding to platelets, since its omission greatly reduced binding, and 10 mmol/L EDTA also inhibited light chain binding. The ability of HK or light chain of HK to bind to platelets was not due to the highly basic, histidine-rich region on this part of the protein, because two peptides, GHKHER and HGLGHGH, derived from this region of the light chain of HK did not inhibit '=I-HK binding (Table 1) . Finally, although LK and HK reciprocally inhibited each other from binding to platelets, LK and the light chain of HK did not mutually exclude each other from binding (Table 1) . LK did not inhibit 'Z51-light chain of HK from binding to platelets, and the light chain of HK did not inhibit '"I-LK from binding ( Table 1) .
Characterization of form and function of platelet-bound HZC Studies were performed to characterize HK bound to platelets. '"I-HK was found to bind to platelets in an unmodified form (Fig 5) . The electrophoretic mobility of lZSI-HK recovered from platelets was identical to the starting lZSI-HK, as well as the unbound portion. Since HK bound to platelets in an unmodified form, further investigations were performed to determine if platelet-bound HK was a substrate for plasma and tissue kallikreins (Figs 6 and  7) . When 1.5 nmol/L soluble '"I-HK was incubated with 4 nmol/L plasma kallikrein, a concentration that represents the activation of less than 1% of plasma prekallikrein, the radioligand was rapidly cleaved (within 1 minute) into a 64-Kd heavy chain and a 56-Kd light chain (seen as two thick bands between the 66-and 43-Kd markers), resulting in less than 6% of the total HK remaining intact at 120 Kd (Fig 6A) . Alternatively, when 1.5 nmol/L platelet-bound "'I-HK was incubated with the same concentration of plasma kallikrein, the rate of cleavage of the platelet-bound HK was retarded when compared with the fluid-phase incubation. Approximately 30% of the radioligand remained intact at 120 Kd after 1 minute (Fig 6C) . Full cleavage of the 120-Kd "'I-HK was completed in the fluid phase by 10 minutes, but even at 120 minutes, some of the platelet-bound "'I-HK remained uncleaved. In this experiment, a control platelet-bound "'I-HK incubated without plasma kallikrein for 2 hours at 37°C also became cleaved. The extent of cleavage was similar to that of platelet-bound "'I-HK incubated with plasma kallikrein for 1 minute. The protection from cleavage only occurred with platelet-bound HK, because any "'I-HK that eluted from the platelets during the incubation was cleaved almost as rapidly as the kininogen incubated in solution with 4 nmol/L plasma kallikrein (Fig 6B) .
Similar findings occurred when recombinant human urinary kallikrein was used as the kininogenase (Fig 7) . In a soluble cleavage reaction (Fig 7A) , 1.5 nmol/L intact 120-Kd "'I-HK was rapidly cleaved by human urinary kallikrein (15 nmol/L) into 64-and 56-Kd bands (which appear as one thick band in Fig 7) . A 46-Kd band faintly appeared at 10 minutes, becoming more prominent at 120 minutes. At 10 minutes, only 5% of the radioligand remained intact. After 10 minutes' incubation, 1.S nmol/L platelet-bound "'I-HK was less cleaved, since 32% of the radioactivity remained at 120 Kd (Fig 7C) . Even at 120 minutes' incubation, 19% of the platelet-bound "'I-HK was intact (120 Kd) and seemed to be resistant to cleavage by human urinary kallikrein. In a control incubation for 2 hours at 37"C, "'I-HK bound to platelets and not treated with kallikrein did not become cleaved (Fig 7C) . The protection of platclet-bound HK from kallikrein cleavage only occurred with the radiolabeled HK that remained platelet-bound. "'I-HK that eluted from the platelets was rapidly cleaved, within 10 minutes, by human urinary For kallikrein, since only 7% of the protein remained at 120 Kd (Fig 7B) .
Although previous reports have shown that clcavage of HK in the patterns seen in Figs 6 and 7 with plasma and urinary kallikrein correlated with bradykinin liberation,'"'" additional studies were pcrformcd to confirm that the clcavage of radiolabeled HK was associated with bradykinin liberation (Fig 8) . As shown in Fig 8, both plasma and urinary kallikrein cleaved HK from an intact band at 120 Kd to a thick band that extends from 64 to 56 Kd. Another faint band at 46 Kd is also seen in the cleavage experiment with plasma kallikrein. On immunoblot of these same kallikrcintreated specimens, mostly cleaved kininogen is seen, although a small quantity of intact 120-Kd HK was detected using an antibody that recognizes both the heavy and light chains of HK (Fig 88) . However, when an antibody to bradykinin, which recognizes on Western blot kinin in intact kininogen: was used for the immunoblot, the starting material only was detected (Fig 8C) . In Fig 8, no intact or kallikrein-clcavcd HKs were seen on the immunoblot with the anti-bradykinin antibody, although faint bands of intact HK at 120 Kd were present on the autoradiogram in support of the findings seen in Fig 8B. These findings indicated that the cleaved kininogen seen in Figs 6 and 7 must be bradykinin-frce. Since platelet-bound HK is protcctcd from kallikrein cleavage, these data indicate that the binding of HK to platelets modulates the rate by which bradykinin can be liberated from this pool of kininogen.
DISCUSSION
HK and LK both serve as the parent proteins for bradykinin. The light chain of HK contains binding regions for artifical surfaces and prckallikrcin and factor XI, which give HK its cofactor role in the activation of the plasma zymogens, factor XII, prckallikrcin, and factor XI.'x '"'" 'I The heavy chain of HK scrvcs as an inhibitor of cysteine proteases?' " including platelet calpain." Expression of HK on platelets or other cell membranes of the vasculature' ' may allow for the integration of thcse three different activities of HK.
Since platelets circulate in a resting statc, we chose to focus our invcstigations on determining which region(s) on HK binds to unstimulated platelets using the purified heavy and light chains of HK. Initial investigations showed that LK and the heavy and light chains of HK indcpcndcntly produced compct itive inhibit ion of l"I-HK-platelct binding (Fig 2) . Since LK directly binds to platclets,H it was expected that the heavy chain of HK could inhibit "'I-HK binding to platelets. To indcpcndcntly confirm these findings and to determine the mechanism and inhibitory constants of the purified heavy and light chains on "'I-HK binding to platelets, concentration-dependent binding experiments were performed in the presence of various compctitors and analyzed by reciprocal plots (Fig 3) . The validity of this cxpcrimcntal approach was confirmed by determining the Ki of HK on "'I-HK binding to platelets. The Ki of 7 to 19 nmol/L produced by HK on "'I-HK binding (Figs 2A and  3A) is similar to the Kd of 15 nmol/L found in rcccnt, dircct "'I-HK binding to unstimulated platelets.
It is important to note that the present values reported by us for thc Kd and Ki for dircct "'I-HK binding to platelets and HKs competitive inhibition of binding of "'I-HK to platelets, respectively, are higher than that we had previously published.' The values reported here represent a recalculation of that published data and the performance of additional experiments. These present values serve to correct those we previously published for "'I-HK binding to unstimulated platelets."
Using the methods of competitive inhibition and concentration-dependent binding experiments in the presence of chains of HK, we wcrc able to determine that, in addition to the purified heavy chain of HK, the purified light chain of HK is also able to indcpcndcntly function as an inhibitor of "'I-HK binding to platelets (Figs 2 and 3 
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facts, IX.IU.JU.II it has bccn assumed without any spccific data that the light chain should contain a domain that binds to cell surfaces. Confirmation of this assumption that the light chain of HK does contain a rcgion that can bind to platclcts is shown by the prcscnt dircct "'I-light chain of HK-platelet binding studies (Fig 4) . '"I-light chain binding to platclcts was spccific, sincc only unlabeled light chain and HK. but not LK, inhibitcd binding (Tablc 1). The zinc rcquircmcnt for light chain binding to platclets may bc necessary to form a bridge bctwccn the platelet surface and thc anionic charged rcgion on domain 5 of thc light chain of HK. Howcvcr, two histidinc-rich peptides from domain 5, one of which binds zinc, did not block "'I-HK binding to platclcts. Thcrcforc, the zinc rcquircmcnt for light chain binding to platclcts may bc for the cxprcssion of thc putativc kininogcn rcccptor, similar to the postulated reason for thc rcquircmcnt of zinc ion for LK binding to platclcts." Although LK inhibits HK binding and HK inhibits LK binding to platclcts, thc finding that purified 56-Kd light chain o f HK did not inhibit "'I-LK binding to platclcts and LK did not inhibit "'I-light chain binding (Tablc 1) indicatcs that the region of LK that binds to platelcts is not thc 12 amino acids on the N-tcrminal portion o f thc light chain. This finding also suggcsts that both binding domains on the light and heavy chains of HK indcpcndcntly intcract with diffcrcnt regions of the platclct surfacc. It is possible that platclcts and pcrhaps other cclls havc two rcccptors for thc kininogcns, one for thc heavy chain domain and another for thc light chain of HK. Howcver, "'I-HK and '"I-LK binding to platclcts havc bccn charactcrizcd as having a singlc saturable site with similar affinitics and numbcr of binding sites'.'' (Tablc 2). This apparent paradox could bc cxplaincd altcrnativcly by onc platclct rcccptor which has 
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contiguous sitcs for binding cach domain on HK. To clarify these altcrnative intcrprctations, further studics are ncccssary to determine the physiochcmical platclct rcceptor(s) for the plasma kininogcns. 
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The Ki (11 to 17 nmol/L) for the light chain and the Ki (17 to 30 nmol/L) for the heavy chain inhibition of '"I-HK binding to platelets are similar to the Kd of direct '"I-HK binding (15 nmol/L) and the Ki (7 to 19 nmol/L) produced by HK inhibition of '"I-HK binding. In previous binding studies with HK to endothelial cells and granulocyte^,^.^ we showed that the Ki calculated from the IC,, and using the formula of Muller@ was similar to the Kd determined by direct binding experiments when binding was performed under equilibrium conditions. The similarity of these binding constants for all forms of the kininogens suggests that when intact HK is bound to platelets, the two portions of the molecule cannot each bind in an optimal manner." This type of noncooperative interaction with an apparent loss of entropy on binding has been noted previously in subunit binding of heavy meromyosin to actins6 and in factor V binding to phospholipid vesicles?' Further, it is of interest that the affinity of both HK and LK8 binding to unstimulated platelets is similar to the affinity of HK binding to granulocytes and endothelial cells5" (Table 2 ). Since the affinity for kininogens' expression on cells within the vasculature is, on average, approximately 20 nmol/L and the plasma concentrations of HK and LK are 600 nmol/L and 2,400 nmol/L, respectively, all the intravascular binding sites for the kininogens must be saturated in vivo. If there is a single platelet receptor that is competed for equally by the plasma kininogens, one could postulate a fourfold greater relative occupancy for LK over HK on the platelet surface. Although the number of sites for the membrane expression of HK varies with the cell type, the density of distribution of HK molecules on each of these cells are similar when adjusted for the surface area of the specific cell type. This finding suggests that there is the potential for the homogeneous expression of the kininogens on cells within the vasculature.
The finding that HK binds to platelets as an intact protein (Fig 5) suggests that it may be processed under certain conditions on the platelet surface. One form of processing of membrane-expressed HK would be to cleave it to liberate bradykinin. Release of bradykinin from plateletbound HK may be physiologically important at sites of platelet plug formation on injured endothelium, because bradykinin is a potent stimulator of endothelial cell function?8-61 HK also binds as an intact protein to endothelial cells,6 although it appears to be cleaved by enzymes associated with endothelial cells.w The finding that plateletbound HK was protected from both plasma and tissue kallikrein cleavage suggests that the membrane expression of HK can serve to modulate the rate of liberation of bradykinin (Figs 6 to 8) . The protection of platelet-bound HK from kallikrein cleavage is physiologically relevant, because it was shown to occur at kallikrein concentrations less than or equal to 1% of potential plasma kallikrein. The higher concentration of human urinary kallikrein (15 nmol/L) needed to achieve similar degrees of HK cleavage as plasma kallikrein (4 nmol/L) is characteristic of HK being the preferred substrate of plasma kallikrein, rather than tissue kallikrein. These findings indicate a new and important finding for the membrane expression of the kininogens. &lodulation of the rate of liberation of bradykinin from cell-bound kininogens may be important in the autocrine regulation of blood pressure. Although the rate of bradykinin liberation from platelet membrane-bound HK is slower than fluid-phase cleavage, bradykinin freed at the cell surface may also be protected from kininases. Further studies are needed to determine whether bradykinin liberated from membrane-bound kininogen can be more influential on the metabolism of cells than an equal quantity liberated in plasma.
